As director of the FDA's CBER, Peter Marks oversees biological products including vaccines, blood and blood products, and cellular, tissue, and gene therapies. A physician and research scientist, he received his graduate degree in cell and molecular biology and his medical degree at New York University. He worked at Brigham and Women's Hospital, in the pharmaceutical industry, and then at Yale University. He joined the FDA in 2012 as deputy director of CBER and became director in 2016. Marks is board certified in internal medicine, hematology and medical oncology and is a Fellow of the American College of Physicians.